68 results about "Ketamine" patented technology

The present disclosure relates to compositions comprising racemic ketamine, or a pharmaceutically acceptable salt thereof, for use in treating psychiatric disorders such as suicidality, suicidal ideation, major depressive disorder, treatment-resistant depression, and post-traumatic stress disorder.

The invention discloses a ketamine derivative and application thereof in treatment of mental diseases, and belongs to the technical field of medicines. The compound or the pharmaceutical composition thereof provided by the invention can obviously improve the expression quantity of nerve cells BDNF, promote the growth of neurite, inhibit NMDA receptor signals and treat acute and chronic depression, has improved oral bioavailability compared with ketamine, and can be used for treating mental diseases such as depression.

The invention provides a sterile, injectable pharmaceutical composition which includes a therapeutically effective amount of ketamine or a pharmaceutically acceptable salt thereof, a nitrite scavenger, a tonicity agent, and water, wherein the composition contains less than about 300 ppb of an N-nitrosoketamine impurity. The invention also provides a pharmaceutical product which includes a container and the composition of the invention aseptically sealed therein. The invention further provides a process for preparing the composition and product of the invention.

Disclosed herein are immediate release oral dosage forms that contain abuse-deterrent and abuse-resistant features. In particular, the disclosed dosage forms can provide deterrence of abuse by ingestion of multiple individual doses. The disclosed dosage forms can likewise provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses. The dosage forms may also exhibit abuse resistant properties when physically manipulated, and also when physically manipulated and then administered in a manner not consistent with oral dosing. The dosage forms may also exhibit abuse resistant properties when administered in a manner intended to result in administration of the esketamine in a higher than therapeutic dose.

The present disclosure provides a method for treating or ameliorating depressive symptoms in a subject, the method comprising administering to the subject a therapeutically effective amount of a composition comprising R(-)-ketamine or a pharmaceutically acceptable salt thereof.

The present invention provides (S)- or (R)-ketamine prodrugs and compositions thereof for the treatment or prevention of depression and pain. [Solution] A compound of formula (1) or a pharmaceutically acceptable salt thereof (wherein R1 is hydrogen or alkyl, and R2 is a group of formula (6)) is provided. JPEG2026123016000361.jpg3980 JPEG2026123016000362.jpg2379

Provided herein are ketamine formulations for subcutaneous injection, in particular subcutaneous formulations of ketamine useful for the treatment of various diseases and disorders. The subcutaneous ketamine preparation provided by the invention reduces stimulation and pain of an injection site.

Methods and compositions that treat Alzheimer's disease and other neurodegenerative diseases and / or to ameliorate or improve symptoms associated with Alzheimer's disease. In some aspects, the compositions and methods use a serotonin 4 receptor (5-hydroxytryptamine (serotonin) receptor 4, or 5-HT4R) agonist in combination with: (R,S)-ketamine, a (R,S)-ketamine analog, or a pharmaceutically acceptable salt, derivative, or metabolite thereof; an antagonist of the glutamate N-methyl-D-aspartate (NMDA) receptor (NMDAR); or an agonist of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor (AMPAR).

Provided herein are subcutaneous formulations of ketamine that are useful for treating a variety of disease and disorders. The subcutaneous ketamine formulations provided herein reduce injection site irritation and pain.

The invention belongs to the technical field of medicines, and particularly relates to an esketamine and mirtazapine synergistic antidepressant pharmaceutical composition and application thereof. The antidepressant pharmaceutical composition comprises the following active components: esketamine and mirtazapine, the esketamine is an N-methyl-D-aspartic acid receptor antagonist, and the mirtazapine is an adrenergic alpha2-AR antagonist. According to the anti-depression pharmaceutical composition containing esketamine and mirtazapine, through the synergistic effect of esketamine and mirtazapine, the effects of reducing dosage, prolonging aging and reducing adverse reactions are achieved, and major depressive disorder is safely and effectively prevented and treated.

The invention provides the composite injection containing ketamine and citalopram, and when the composite injection is used for treating depressive disorder, the composite injection takes effect more quickly and responds more accurately, the effect delay period can be further shortened, and the anti-depression curative effect can be further improved. And the medicine is more convenient to take, and the medication compliance is greatly improved.

The application belongs to the technical field of medicine, and discloses application of oxeladin in preparation of a medicine for preventing or treating perioperative hypothermia. The dose of the medicine ranges from 1 to 3 mg. The medicine is applied to perioperative hypothermia caused by general anesthesia. The general anesthesia includes sevoflurane and esketamine. The medicine further comprises a pharmaceutically acceptable carrier and / or excipient. It is found in the previous application that the incidence of hypothermia and chills after general anesthesia is significantly reduced in the oxeladin administration group compared with the blank control group, and the further verification is carried out through animal experiments. The achievement of the application provides an effective prevention and treatment scheme for improving perioperative hypothermia and chills in clinic.

The invention relates to pharmaceutical compositions comprising ketamine or pharmaceutically acceptable salt thereof for nasal administration, and methods for using such compositions.

The invention relates to the technical field of biological analysis and detection, in particular to a cucurbituril derivative for drug detection, a preparation method and application of the cucurbituril derivative, a detection probe containing the cucurbituril derivative, a drug for treating acute poisoning of drugs and a drug detection method. On the basis of retaining the original supramolecular recognition characteristic of cucurbituril, the derivative introduces an o-cyanobenzaldehyde (CNBA) functional group; the obtained compound can realize high-efficiency covalent capture on common drugs and metabolites thereof (such as primary amine groups in molecules of methylamphetamine and metabolites thereof, 3, 4-methylenedioxy methylamphetamine, ketamine and metabolites thereof, fluazinone and metabolites thereof, phencyclohexylpiperidine, cathinone and the like); therefore, rapid and high-sensitivity visual detection of the target object is realized, and the method can be used for antagonistic treatment of acute poisoning caused by related drugs and metabolites.

The present invention features methods and compositions for the treatment of an emotional disorder in a subject by administering ketamine, norketamine, 6-hydroxynorketamine, or a pharmaceutically acceptable salt thereof, and cannabis or a cannabinoid in an amount that is sufficient to treat the emotional disorder.

The present invention relates to an oral dosage form for administration of ketamine and a method of preparing an oral dosage form for administration of ketamine, preferably once or twice a day.

The present disclosure provides compositions containing ketamine and methods of using those compositions for the treatment of post-traumatic stress disorder.

The invention belongs to the technical field of medicines, and particularly relates to an antidepressant pharmaceutical composition and application thereof. The antidepressant pharmaceutical composition is prepared from the following active ingredients: esketamine and mianserin, the esketamine is an N-methyl-D-aspartic acid receptor antagonist, and the mianserin is a central presynaptic adrenergic alpha2-AR antagonist. The invention further discloses a preparation method of the pharmaceutical composition. Escketamine and mianserin play an anti-depression role in different ways, and after combined use, not only is the drug dosage of the escketamine reduced, but also the anti-depression action time of the escketamine is prolonged, and a synergistic amplification effect is generated.

The disclosure provides a method of treating or ameliorating depressive symptoms of a subject, comprising administering a therapeutically effective amount of a composition comprising R(−)-ketamine, or a pharmaceutically acceptable salt thereof, to the subject.

The present invention relates to a dosing regimen of 2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one, also known as ketamine, or a derivative thereof for use in the treatment of depression, in particular treatment resistant depression.

The application belongs to the technical field of biological medicine, and relates to a drug for treating depression, and in particular to application of cyclopentolate combined with esketamine in preparation of a drug for treating depression. Experimental researches of the application show that, compared with cyclopentolate or esketamine alone, cyclopentolate combined with esketamine can more significantly improve the depressive behavior of CRS depressive model mice, and it is proved that cyclopentolate combined with esketamine can synergistically enhance the anti-depression effect, so as to be used as a drug for treating depression.

This invention relates to the field of pharmaceutical technology, and in particular to a cleaved C19 diterpenoid alkaloid compound and its application in rapid-acting antidepressants. This invention isolates a novel cleaved C19 diterpenoid alkaloid compound, Carmaloidline G, from Aconitum carmichaelii and establishes a stable and controllable extraction, separation, and purification process, achieving high-purity preparation and industrial-scale feasibility of this compound. Studies have shown that this compound exhibits significant rapid-acting antidepressant activity in various animal models of depression, with a fast onset of action and stable efficacy. Its overall efficacy is comparable to the positive control drug esketamine, but the required dosage is significantly reduced, thereby effectively reducing the risk of potential adverse reactions.

The present invention is directed to oral neuro-attenuating ketamine (NAKET) tablet formulations, and methods of administration, which ensure the steady release of a therapeutically effective concentration of ketamine from an oral tablet without neurologically toxic spikes in ketamine concentration. In particular, the present invention provides single layer oral tablet formulation of NAKET. In a specific embodiment, the NAKET tablet formulation, and methods of administration provide steady administration of NAKET to a subject for 24 hours or greater, for example, up to 36 hours, after a single administration event.

Provided is a novel compound having rapid and long-lasting therapeutic effects on diseases exhibiting depressive symptoms. Specifically, provided are an agent for prevention and / or treatment of a depressive symptom, consisting of R(−)-ketamine or a pharmacologically acceptable salt thereof, and a pharmaceutical composition for prevention and / or treatment of a depressive symptom, comprising R(−)-ketamine or a pharmacologically acceptable salt thereof in an effective amount for reducing a depressive symptom, and being substantially free of S(+)-ketamine, and a pharmacologically acceptable salt thereof.

The present application relates to the technical field of biological analysis detection, and particularly relates to cucurbituril derivatives for drug detection, a preparation method and application of the cucurbituril derivatives, a detection probe containing the cucurbituril derivatives, a drug for treating drug acute poisoning, and a method for drug detection. The derivative introduces a functional group of o-cyanobenzaldehyde (CNBA) on the basis of retaining the original supramolecular recognition characteristics of cucurbituril, and the obtained compound can realize efficient covalent capture on the primary amine groups in common drugs and metabolites (such as methyl phenylpropylamine and its metabolites, 3,4-methylenedioxy methyl phenylpropylamine, ketamine and its metabolites, fluoroamine and its metabolites, phenylcyclohexylpiperidine, and casiketone molecules), so as to realize rapid, high-sensitivity and visual detection on the above target objects, and can be used for antagonistic treatment of acute poisoning caused by related drugs and metabolites.

The present disclosure relates to compositions comprising racemic ketamine or a pharmaceutically acceptable salt thereof for use in the treatment of psychiatric disorders such as suicide propensity, suicide idea, major depression, anti-therapeutic depression, and post-traumatic stress disorders.

Provided herein are pharmaceutical compositions comprising midazolam and ketamine, and methods of inducing sedation (e.g., procedural sedation) in a subject using administration of such compositions, the compositions optionally including a pharmaceutically active compound of a third class. Compositions may be in sublingual or buccal form, or incorporated into vehicles for extended release. Methods for fabricating the compositions and using them for anesthesiological applications are also described.